Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1
Others Struggle To Raise Ratio
Executive Summary
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
You may also be interested in...
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
Cage Fighting: Novel Drugs From MNCs, Chinese Rivals Compete In China Reimbursement Sector
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.
Chinese-Language Podcast: ESMO上的中国数据
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.